An Open-label, Phase I, Dose Escalation Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0575 Administered Alone and in Combination With Gemcitabine in Patients With Refractory Solid Tumors or Lymphoma
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 16 Aug 2017
At a glance
- Drugs GDC 0575 (Primary) ; Gemcitabine
- Indications Lymphoma; Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Genentech
- 14 Aug 2017 Planned End Date changed from 2 Jun 2017 to 2 Jun 2018.
- 14 Aug 2017 Planned primary completion date changed from 2 Jun 2017 to 2 Jun 2018.
- 02 Dec 2016 Results assessing preclinical and clinical activity of GDC-0575 and gemcitabine (n=2) presented at the 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics